Rubel & Ménasché has sold a minority stake to Axio Capital
The private shareholders of Rubel & Ménasché have sold a minority stake in the company to AXIO CAPITAL. Financial details have not been disclosed.
Rubel & Ménasché is a renowned French diamond dealer specialized in the sale of small stones, smaller than one carat. Due to a robust organization, Rubel & Ménasché masters the entire supply chain, from the purchase of stones to the sale, including customers' support. Headquartered in Paris and based on its unique know-how and service-oriented positioning, the company benefits from long-standing relationships with blue chips clients such as Cartier, Van Cleef & Arpels and Boucheron. In 2018, the company generated revenues of US$65 million and an EBITDA of US$4.8 million.
AXIO CAPITAL is a French PE fund which focuses on SMEs with a turnover between US$3.5–110 million in sales in all sectors.
Oaklins' team in France advised the sellers in this transaction.
Talk to the deal team
Related deals
OBI Group has acquired the OBI and individual DIG stores from Migros
As part of a strategic review, Migros has decided to divest its DIY business, which included several “Do It + Garden” and “OBI” locations. Migros had operated the Swiss OBI stores as a franchisee. In OBI Group Holding, Migros has found the ideal partner to ensure continuity for both its customers and employees.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more